Tubulis
Munich
About Tubulis
Tubulis generates uniquely matched antibody-drug conjugates (ADCs) using proprietary platform technologies. The company's pipeline includes lead ADC candidates, TUB-040 and TUB-030, which are being evaluated in the clinic for high-need solid tumor indications. Tubulis innovates on all aspects of ADC design to expand the therapeutic potential of this drug class for patients.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 51 – 100
- Total funding: $616.9M
- Funding stage: Late Stage Venture
- Last round: Series C (Oct 2025)
- Website: tubulis.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Health Care, Life Science, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/tubulis-56990 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.